Regenerative biotechnology
Heterologous Natural Killer Cells Blockade
Heterologous Natural Killer cells with dual immune blockade for antitumor therapy.
Heterologous Natural Killer cells that combine pretreatment with nivolumab and ipilimumab, based on the enhancement of the innate and adaptive immune system to effectively combat tumor cells.
Composition
7 million heterologous NK cells pretreated with Nivolumab and Ipilimumab.
Pharmaceutical form
Intravenous injectable solution.
Presentation
Monovette with 4 ml.
Therapeutic Properties
Mechanism of action. Pretreatment blocks tumor immune evasion, allowing NK and T cells to recognize and attack protected tumor cells.
- Enhancement of the immune system.
- Increased cytotoxic activity.
- They induce tumor apoptosis.
- Strengthens the immune response.
- Increases lymphocyte proliferation.
- Long-term control.
Mechanism of action & Clinical data
Heterologous NK cells, obtained from healthy donors, enhance the ability to attack tumor cells.